1832 Asset Management
CMTA

1832 Asset Management’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

1832 Asset Management’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,000
Closed -$11K – 747
2018
Q3 		$11K Hold
1,000
– – ﹤0.01% 590
2018
Q2 		$11K Hold
1,000
– – ﹤0.01% 567
2018
Q1 		$15K Buy
+1,000
New +$16.3K ﹤0.01% 587

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

1832 Asset Management's CMTA Position: Q4 2018 in Review

1832 Asset Management sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q4 2018, closing a stake of 1,000 shares — an estimated $11K sold.

1832 Asset Management first reported a position in CMTA in Q1 2018 and held it in 3 quarters. The position peaked at $15K in Q1 2018. 31 funds tracked by Wall St. Rank hold CMTA as of Q4 2018.

  • 1832 Asset Management reported no remaining Clementia Pharmaceuticals Inc. position as of Q4 2018 after selling out during the quarter.
  • 1832 Asset Management sold 1,000 Clementia Pharmaceuticals Inc. shares in Q4 2018, an estimated $11K.
  • 1832 Asset Management first reported a position in Clementia Pharmaceuticals Inc. in Q1 2018 and held it in 3 quarters.
  • 1832 Asset Management's Clementia Pharmaceuticals Inc. position peaked at $15K in Q1 2018.
  • 31 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q4 2018.

Based on 1832 Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.